CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 30 enrolled
Drug / intervention
Nivolumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03789110
NCT03789110Phase 2Active
CompareCT.gov

NIMBUS: A Phase II Study of Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer

Dana-Farber Cancer Institute·interventional·Posted Dec 28, 2018·Updated Apr 28, 2026

In Brief

A Phase 2 clinical trial evaluating Nivolumab and Ipilimumab for Breast Cancer. Active but no longer recruiting, targeting 30 participants across 3 sites.

Detailed Summary

This research study is studying a drug combination of nivolumab and ipilimumab as a possible treatment for hypermutated HER2 negative breast cancer. The drugs involved in this study are: * Nivolumab (Opdivo ®) * Ipilimumab (Yervoy ®)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
CollaboratorsBristol-Myers Squibb

Timeline

Phase 2Active
201920202021202220232024202520262027
First PostedDec 28, 2018
Enrollment StartMar 8, 2019
Primary CompletionSep 30, 2021
Study CompletionFeb 28, 2027
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 7.5 years ago

Interventions

Nivolumabdrug

Nivolumab is called an anti- PD-1 or a checkpoint inhibitor and is an antibody (a type of human protein) designed to allow the body's own immune system to destroy tumors

Ipilimumabdrug

Ipilimumab is called an anti-CTLA-4 and is a type of antibody that works to prevent the body's immune system from stopping to fight a specific cancer